[Biochemical markers of toxic and mutagenic complications of cytostatic pharmacotherapy].
Data are submitted on individual prophylaxis of damage to the genetical apparatus of bodily normal cells in cytostatic therapy of immunodeficiency states by observing changes in biochemical indices, such as activity of enzymes, content of biologically active substances and hormones.
Serhieieva
L A
LA
Chelpan
L L
LL
Maĭlian
E A
EA
Kurbatov
V V
VV
D015415:Biomarkers / Q000097:blood*; D002648:Child; D002802:Cholinesterases / Q000097:blood; D006801:Humans; D007154:Immune System Diseases / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000097:blood; D011379:Prognosis; D000516:alpha-Amylases / Q000097:blood
D015415:Biomarkers; D007166:Immunosuppressive Agents; D018836:Inflammation Mediators; D002802:Cholinesterases; D000516:alpha-Amylases
Biokhimichni kryteriï toksychnykh i mutahennykh uskladnen' tsytostatychnoï farmakoterapiï.